Vimarsana
Biggest News Aggregation in the World

Page 2 - Revised Forecast News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Revised Forecast. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Revised Forecast Today - Breaking & Trending Today

Advance Residence Investment : Notice Concerning Revision to Forecast of Financial Results -Today at 02:52 am - Vimarsana News

Advance Residence Investment : Notice Concerning Revision to Forecast of Financial Results -Today at 02:52 am

1,051 984 ...

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2023 SECOND QUARTER FINANCIAL RESULTS - Vimarsana News

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2023 SECOND QUARTER FINANCIAL RESULTS

/PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $171.3 million, or $2.42 per...

Lasertec : Revised Forecasts of Consolidated Financial Results and Year-End Dividend for FY2023, and Forecast of Consolidated Financial Results for FY2024 - Vimarsana News

Lasertec : Revised Forecasts of Consolidated Financial Results and Year-End Dividend for FY2023, and Forecast of Consolidated Financial Results for FY2024

FOR IMMEDIATE RELEASE Lasertec Corporation 2-10-1Shin-yokohama,Kohoku-ku, Yokohama Revised...

Bristol-Myers Squibb Is Still An Attractive Addition To Your Dividend Growth Portfolio - Vimarsana News

Bristol-Myers Squibb Is Still An Attractive Addition To Your Dividend Growth Portfolio

Bristol-Myers Squibb has strong fundamentals, attractive valuation, and decent growth prospects. Read why investors should consider BMY for their dividend growth portfolio.

Bristol Myers to drop some drug programs due to U.S. pricing reforms – FT (NYSE:BMY) - Vimarsana News

Bristol Myers to drop some drug programs due to U.S. pricing reforms – FT (NYSE:BMY)

Bristol Myers Squibb (BMY) says that recently-introduced U.S. drug pricing reforms will force the company to cancel some drug development programs...